HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christophe Bonny Selected Research

D-JNKI-1

7/2010JNK inhibition and inflammation after cerebral ischemia.
4/2010c-Jun N-terminal kinase signaling pathway in excitotoxic cell death following kainic acid-induced status epilepticus.
1/2010c-Jun N-terminal kinase pathway inhibition in intracerebral hemorrhage.
1/2008The JNK inhibitor XG-102 protects from ischemic damage with delayed intravenous administration also in the presence of recombinant tissue plasminogen activator.
4/2007Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity.
4/2007A peptide inhibitor of c-Jun NH2-terminal kinase reduces myocardial ischemia-reperfusion injury and infarct size in vivo.
3/2007Inhibition of the c-Jun N-terminal kinase-mediated mitochondrial cell death pathway restores auditory function in sound-exposed animals.
6/2006D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma.
3/2006A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance.
7/2004D-JNKI1, a cell-penetrating c-Jun-N-terminal kinase inhibitor, protects against cell death in severe cerebral ischemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christophe Bonny Research Topics

Disease

8Ischemia
05/2013 - 05/2004
4Brain Ischemia (Cerebral Ischemia)
07/2010 - 09/2003
4Stroke (Strokes)
07/2010 - 09/2003
3Hypoxia (Hypoxemia)
05/2013 - 07/2006
3Infarction (Infarctions)
07/2010 - 07/2004
3Hearing Loss (Hearing Impairment)
04/2007 - 06/2006
3Wounds and Injuries (Trauma)
04/2007 - 06/2006
3Neoplasms (Cancer)
04/2005 - 09/2004
2Pain (Aches)
05/2012 - 03/2006
2Neuralgia (Stump Neuralgia)
05/2012 - 03/2006
2Seizures (Absence Seizure)
03/2012 - 04/2010
2Ischemic Stroke
01/2010 - 01/2008
2Insulinoma
06/2008 - 04/2005
2Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2008 - 07/2004
2Noise-Induced Hearing Loss (Acoustic Trauma)
04/2007 - 01/2005
1Crohn Disease (Crohn's Disease)
05/2022
1Perinatal Death
05/2013
1Peripheral Nerve Injuries
05/2012
1Inflammation (Inflammations)
07/2010
1Ganglion Cysts (Ganglion)
06/2010
1Optic Nerve Injuries
06/2010
1Gliosis
04/2010
1Status Epilepticus (Complex Partial Status Epilepticus)
04/2010
1Cerebral Hemorrhage
01/2010
1Brain Edema (Cerebral Edema)
01/2010
1Insulin Resistance
06/2008
1Infections
07/2007
1Central Nervous System Infections (Central Nervous System Infection)
07/2007
1Encephalitis (Encephalitis, Rasmussen)
07/2007
1Reoviridae Infections
07/2007
1Virus Diseases (Viral Diseases)
07/2007
1Viral Encephalitis
07/2007
1Necrosis
04/2007
1Deafness (Deaf Mutism)
04/2007
1Ototoxicity
04/2007
1Reperfusion Injury
04/2007
1Myocardial Ischemia (Ischemic Heart Diseases)
04/2007
1Hyperalgesia
03/2006
1Type 1 Diabetes Mellitus (Autoimmune Diabetes)
12/2003
1Hereditary Corneal Dystrophies
07/2003
1Type 2 Diabetes Mellitus (MODY)
09/2002

Drug/Important Bio-Agent (IBA)

14JNK Mitogen-Activated Protein KinasesIBA
05/2012 - 09/2003
13Peptides (Polypeptides)IBA
05/2013 - 09/2003
10D-JNKI-1IBA
07/2010 - 07/2004
5Phosphotransferases (Kinase)IBA
03/2012 - 07/2006
3CytokinesIBA
05/2022 - 12/2003
3Glucose (Dextrose)FDA LinkGeneric
07/2010 - 01/2008
3Neuroprotective AgentsIBA
01/2008 - 09/2003
3Mitogen-Activated Protein KinasesIBA
04/2007 - 07/2006
2N-Methylaspartate (NMDA)IBA
05/2013 - 06/2010
2Protein Isoforms (Isoforms)IBA
05/2012 - 04/2007
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
03/2012 - 07/2006
2Kainic Acid (Kainate)IBA
03/2012 - 04/2010
2Oxygen (Dioxygen)IBA
07/2010 - 01/2008
2Caspase 3 (Caspase-3)IBA
07/2007 - 04/2005
2AminoglycosidesIBA
04/2007 - 01/2005
2Peptide Hydrolases (Proteases)FDA Link
09/2004 - 09/2003
1Glycoproteins (Glycoprotein)IBA
05/2022
1LectinsIBA
07/2010
1Retinaldehyde (Retinal)IBA
06/2010
1Glial Fibrillary Acidic ProteinIBA
04/2010
1mitochondrial K(ATP) channelIBA
06/2008
1LeptinIBA
06/2008
1Pharmaceutical PreparationsIBA
01/2008
1NeomycinFDA LinkGeneric
04/2007
1Cytochromes c (Cytochrome c)IBA
03/2007
1Protein Kinases (Protein Kinase)IBA
03/2007
1fodrinIBA
03/2007
1Mitogen-Activated Protein Kinase 3IBA
07/2006
1polypeptide CIBA
03/2006
1Proteasome InhibitorsIBA
04/2005
1Proteasome Endopeptidase Complex (Proteasome)IBA
04/2005
1Insulin (Novolin)FDA Link
04/2005
1leucylleucine (Leu-Leu)IBA
04/2005
1Anti-Bacterial Agents (Antibiotics)IBA
01/2005
1Cisplatin (Platino)FDA LinkGeneric
11/2004
1MutagensIBA
11/2004
1Mitoxantrone (Novantrone)FDA LinkGeneric
11/2004
1CaspasesIBA
11/2004
1Doxorubicin (Adriamycin)FDA LinkGeneric
11/2004
1ElementsIBA
07/2003
1HCEIBA
07/2003
1DNA (Deoxyribonucleic Acid)IBA
09/2002

Therapy/Procedure

4Therapeutics
05/2012 - 11/2004
2Electrodes (Electrode)
04/2007 - 06/2006
1Analgesia
05/2012
1Intravitreal Injections
06/2010
1Injections
04/2010
1Intravenous Administration
01/2008
1Intravenous Injections
01/2008
1Cochlear Implantation
06/2006
1Cochlear Implants (Cochlear Implant)
06/2006
1Ligation
03/2006
1Sutures (Suture)
07/2004